TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* 18 - 65 years~* Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)~* Initial infection \> 1 year ago~* ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy)~* ≥ 2 recurrences during the six-month baseline period~Exclusion Criteria:~* Known or suspected allergy or intolerability to PEG~* Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial~* Pregnancy and/or breast-feeding~* History of malignant diseases (described in chapter 7.2)~* Known or suspected non-compliance to study protocol~* Participation in another investigational drug study in the last 30 days prior to baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PEG-Formulation (Type: EXPERIMENTAL): PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria :~* Postmenopausal ambulatory women~* Established osteoporosis~Exclusion criteria:~* History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission,~* Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Inpatient at Kosair Children's Hospital.~2. Order placed by treating team for MRI of the brain with sedation.~3. Age less than or equal to 18 years.~4. Plan to sedate with dexmedetomidine, regardless of study participation.~Exclusion Criteria:~1. Previous adverse reaction to dexmedetomidine or clonidine~2. Current use of clonidine as a routine medication~3. Concurrent use of a heart-rate decreasing medication (digoxin, propranolol)~4. Contraindication to ketamine use~   * Intracranial hypertension or traumatic brain injury~  * Intraocular hypertension of eye trauma~  * Pulmonary hypertension requiring medical management~5. Planned additional procedure during the sedation encounter (non-brain MRI, lumbar puncture, EEG etc)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine and Ketamine (Type: EXPERIMENTAL): Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
- Dexmedetomidine and Midazolam (Type: ACTIVE_COMPARATOR): Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Protected Environment Rooms for AML and MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* AML or high-risk MDS (\> 10% blasts in the marrow or blood)~* Patient is to be given targeted therapy. Examples of targeted therapies are tipifarnib + low-dose ara-C, decitabine, and 5 azacitidine + valproic acid.~* Age \>/= 60 years and Zubrod performance status of 0,1, or 2~* Informed consent obtained~Exclusion Criteria:~* Cannot receive ara-C at a dose \>/= 100 mg/m2 daily, anthracyclines, or cloretazine.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protective environment (Type: None): Participants in a Protective environment
- Not a protective environment (Type: None): Participants not in a protective environment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be less then 70 years old.~* Patients must have chemosensitive disease, having undergone at least partial remission with less then 10% marrow involvement by gross pathologic examination if autologous transplantation is considered.~* Newly diagnosed patients are eligible for autologous transplant. Patients in relapse would receive a non-myeloablative transplant if a sibling donor is available. Otherwise, patients would undergo autologous transplant if International Prognostic Index (IPI) is 0-1, or unrelated transplant if IPI is \> 1.~Exclusion Criteria:~* Criteria for exclusion are Human immunodeficiency virus (HIV) or Human T-lymphotropic virus (HTLV) seropositivity, pregnancy, cardiac ejection fraction by echo-cardiogram less than 40%, active central nervous system involvement, serum creatinine greater than 1.6 mg/dl or serum bilirubin greater than 1.5 mg/dl unless due to tumor, Absolute neutrophil count (ANC) less than 1,000/mm3 and platelets less than 100,000/mm3 unless due to tumor, performance status (ECOG scale) greater than 2, pulmonary function test- diffusing capacity of the Lung for Carbon Monoxide (DLCO) less than 40% of predicted, and severe concomitant medical or psychiatric illnesses.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Campath-1H (Type: EXPERIMENTAL): 3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with melanoma and determined, by their physician, to be appropriate for DecisionDx-Melanoma testing and who have successful results available to the investigator are eligible for registration~* Patients enrolled should be reasonably able to follow-up with the enrolling physician at regular intervals for assessment of outcome data.~* 16 Years and older~Exclusion Criteria:~* Less than 16 Years of age

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult women (age \>= 18),~* with Histologically documented newly diagnosed stage II-IV invasive breast cancer appropriate for neoadjuvant (preoperative) systemic therapy.~* ECOG performance status of 0, 1, or 2 at the initiation of the study.~Exclusion Criteria:~* pregnant women~* women with contralateral mastectomies~* known bilateral tumors~* subjects prone to claustrophobia~* contraindicated to have MRI~* mentally impaired~* not fluent in english

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oocyte Cryopreservation by Slow Freezing and Vitrification

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 21 and 50 years, at the time of informed consent.~* Subjects must agree to undergo intracytoplasmic sperm injection (ICSI)~Exclusion Criteria:~* Presence of any medical condition that contraindicates ovarian stimulation, in vitro fertilization or pregnancy.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Slow Freezing (Type: EXPERIMENTAL): oocytes will be frozen by slow freeze/ rapid thaw
- Vitrification (Type: EXPERIMENTAL): oocytes will be frozen using rapid freezing/rapid thaw

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed patient informed consent~2. Shallow osteochondral defect ≤ 12 mm diameter and ≤ 8 mm depth in weight bearing area~3. Agree to actively participate in a rehabilitation protocol~Exclusion Criteria:~1. Severe vascular or neurological disease~2. Uncontrolled diabetes~3. Severe degenerative joint disease~4. Pregnancy~5. Presence of infection at the site or in the joint space (e.g. osteomyelitis)~6. Diagnosis rheumatoidism~7. Advanced osteoarthritis as judged by the surgeon~8. Drug and/or alcohol abuse~9. Hypercalcemia~10. Known allergy to any of the components of the device (e.g. bovine collagen)~11. Bleeding disorders of any etiology~12. Steroidal or immunosuppressive maintenance therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Osteochondral lesions (Type: None): Patients with osteochondral lesions in the knee, the ankle, or other joint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Presenting for Cardiology consult at M.D. Anderson Cancer Center.~2. Platelet count between 100,000 and 20,000.~3. Acute Coronary Syndrome diagnosed with their first 12 lead EKG.~4. Patients that continue to show evidence of MI by cardiac enzymes with CPK levels \> 2 normal limits, CK-MB levels 10% above normal limits, and Troponin I levels \> 1.4ug/L will be considered positive for MI.~5. Ability to give consent.~Exclusion Criteria:~1. Contraindications to aspirin including severe intolerance or true allergy, active bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active peptic ulcer, or other significant source of gastrointestinal or genitourinary bleeding, brain metastasis, and altered mental status.~2. Unwillingness or inability to give consent.~3. Progressive heart failure, unstable angina not responding to medical therapy for 24 hours, or ventricular tachycardia, necessitating thrombolysis, and angioplasty.~4. Patients that rule out for MI by cardiac enzymes panel after the first 24 hours.~5. Patients that rule in for MI and have Platelet count \> 100,000.~6. Patients with platelet count \< 20,000.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Model in Evaluating Clinical, Psychosocial, and Health Economic Factors in Adolescent and Young Adult Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with cancer~* ADDITIONAL GRANT SPECIFIC INCLUSION CRITERIA - UNIHEALTH (NORRIS):~* Patients who were diagnosed at USC Norris Comprehensive Cancer Center and Hospital~* Patients who are currently receiving treatment for a primary or secondary tumor at USC Norris Comprehensive Cancer Center and Hospital~* ADDITIONAL GRANT SPECIFIC INCLUSION CRITERIA - QUEENSCARE (LAC + USC):~* Patients who are being seen in sarcoma, gynecologic oncology, or genitourinary clinic at LAC + USC (clinics A2C or 4P1)~* Patients who are currently receiving treatment for a primary or secondary tumor at LAC + USC and who receive oncology care from one of the clinics above~* Patients who are at or below the poverty level~Exclusion Criteria:~* Inability to sign informed assent and/or consent~* Patients who are not receiving chemotherapy and/or radiation therapy for a primary or secondary tumor~* Primary oncology treatment team believes that participation in AYA at USC would not benefit their patient~* ADDITIONAL GRANT SPECIFIC EXCLUSION CRITERIA - UNIHEALTH (NORRIS):~* Patients who are not receiving treatment for a primary or secondary tumor at USC Norris Comprehensive Cancer Center and Hospital~* ADDITIONAL GRANT SPECIFIC EXCLUSION CRITERIA - QUEENSCARE (LAC+USC):~* Patients who are not receiving oncology care for a primary or secondary tumor in sarcoma, gynecologic oncology, or genitourinary clinic at LAC + USC (clinics A2C or 4P1)~* Patients who are above the poverty level

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Observational (questionnaires) (Type: None): Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and sign the written informed consent~* Subjects should have either normal renal function or have stable renal disease~Exclusion Criteria:~* History of heart disease~* Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- A-Patients with mild renal impairment (Type: EXPERIMENTAL): None
- B-Healthy subjects matched to Group A (Type: EXPERIMENTAL): None
- C-Patients with moderate renal impairment (Type: EXPERIMENTAL): None
- D-Healthy subjects matched to Group C (Type: EXPERIMENTAL): None
- E-Patients with severe renal impairment (Type: EXPERIMENTAL): None
- F-Healthy subjects matched to Group E (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Conditions for Patient Eligibility~Each patient must meet all of the following inclusion criteria to be enrolled in the study:~* Histologically or pathologically confirmed melanoma, renal cancer or prostate cancer.~* Patients with melanoma or renal cancer must have metastatic disease.~* Patients with melanoma or renal cancer must have radiographically measurable advanced disease. Patients with measurable cutaneous lesions are also evaluable patients with prostate cancer must be castrate refractory and must have radiographically assessable metastatic disease or must have rising PSA on two sequential measurements.~* No prior chemotherapy, or have not received cytotoxic chemotherapy within the 6 months prior to entry..~* No radiation for 3 weeks prior to beginning Naltrexone~* No requirement for opioid analgesics orNo use of opioid analgesics for at least 10 days.~* Absolute neutrophil count ≥ 1,000/uL, platelet ≥ 75,000/uL.~* Total bilirubin ≤ 1.5x upper institutional limit (ULN) and AST or ALT ≤ 3x ULN;~* No prior history of hepatic failure, cirrhosis or hepatic encephalopathy~* ECOG performance status 0 to 2.~* Creatinine \< 1.5 x ULN~* Life expectancy of at least 8 weeks.~* Age ≥ 18 years~* Women of childbearing potential must have a negative pregnancy test.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 1 months thereafter.~* Voluntary written informed consent.~* Conditions for Patient Ineligibility Patients meeting any of the following exclusion criteria are not to be enrolled in the study.~* Must not have uncontrolled severe, intercurrent illness.~* Women who are breast-feeding.~* Patients who have undergone major surgery or radiotherapy within the last 3 weeks.~* Patients on concurrent anticancer therapy.~* Patients with known, untreated brain metastasis~* Co-medication that may interfere with study results; e.g opioids~* Known hypersensitivity to any component of naltrexone~* Current or prior alcohol dependence~* Patients who could benefit from conventional therapy are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Naltrexone (Type: EXPERIMENTAL): LDN, 5 mg/day-(1 cycle = 28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Cutaneous Reinnervation After Burn

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Major patients~* At least one year back deep burn (2nd and 3rd degrees), and allowing the comparison between the post-burn scar dermatome and the healthy opposite dermatome~* Patients always followed in the service of Plastic surgery of the hospital of Brest~* Informed consent and paper of the patient after information of the objective of the study and the protocol~* Analog Visual scales for pain and/or pruritus (EVA): greater than or equal to 3~* Simple Verbal scales for the pain and/or the pruritus ( EVS): pain / pruritus moderated to intense~* Membership to the Social Security~Exclusion Criteria:~* Allergy to xylocaine~* Non-Caucasian patients~* Treatments having an effect on the pain and/or the pruritus~* Sun or UV exposure several days preceding or following the biopsies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Skin biopsy (Type: OTHER): On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues